Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database
Kaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1539-1549
Closed Access | Times Cited: 7

Showing 7 citing articles:

Emerging Targeted Therapies in Non-Small-Cell Lung Cancer (NSCLC)
Syeda A. Mina, Mohamed Shanshal, Konstantinos Leventakos, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 353-353
Open Access | Times Cited: 1
EML4-ALK: Update on ALK Inhibitors
Alessandra Bearz, Elisa Bertoli, Brigida Stanzione, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 1, pp. 308-308
Open Access
Réarrangement de ALK dans le cancer pulmonaire non à petites cellules
G. Naulleau, Gary Birsen, Audrey Mansuet‐Lupo, et al.
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S86-3S94
Closed Access
Caractérisation moléculaire des cancers du poumon : mise au point et recommandations
Simon Garinet, Audrey Mansuet‐Lupo, Diane Damotte, et al.
Bulletin du Cancer (2025) Vol. 112, Iss. 3, pp. 3S16-3S23
Closed Access
Critical Evaluation of Methodologic Approaches in ALK Tyrosine Kinase Inhibitor Research: Addressing Confounding Factors and Statistical Robustness
Wenqin Wang, Xiangzhi Li, Dan Shan
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. e64-e65
Closed Access | Times Cited: 1
Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database”
Jia Zhang, Guoying Wang, Xiaoming Zhou
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. e63-e64
Closed Access | Times Cited: 1
Precision medicine with MET exon 14: a partial success
Quincy S-C Chu
The Lancet Oncology (2024) Vol. 25, Iss. 10, pp. 1249-1251
Closed Access
Author’s Response to: Comment on “Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM Database” and “Critical Evaluation of Methodological Approaches in ALK TKI Research: Addressing Confounding Factors and Statistical Robustness”
Kaushal Parikh
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. e66-e67
Closed Access
EML4-ALK Variants and Co-Occurring TP53 Mutations in a Real-World Treatment Setting: Do They Matter?
Alessandra Bearz, Mónica Schiappacassi
Journal of Thoracic Oncology (2024) Vol. 19, Iss. 11, pp. 1489-1491
Closed Access
Page 1

Scroll to top